Acarix Makes Strides in U.S. Reimbursement for CADScor System
Recently, Acarix, a pioneering company in the realm of rapid AI and acoustic-based cardiac diagnostics, announced a significant development regarding its CADScor System. The U.S. Centers for Medicare & Medicaid Services (CMS) has designated the CPT code 0716T for the CADScor System, effective for calendar year 2025. This pivotal ruling allows the CADScor System to be assigned to APC 5733 with a status indicator of 'S', indicating that it is now separately payable for services rendered in outpatient settings.
What This Means for Acarix's Growth
Aamir Mahmood, President and CEO of Acarix, expressed that obtaining guaranteed reimbursement for the CADScor System is a tremendous victory for the company. This development is expected to facilitate accelerated growth within the United States across various healthcare settings. Mahmood noted, "Having a predetermined reimbursement structure for the CADScor as a standalone service rather than bundled with other diagnostic tests provides clarity as we anticipate growing demand for its use."
The approval by CMS ensures that healthcare providers can submit claims for the CADScor System used in various outpatient scenarios, including emergency rooms and ambulatory surgical centers. This separate coding establishes a foundation for broad acceptance and integration of the technology in critical settings, streamlining the administrative process for technicians and physicians.
Anticipated Impact on Cardiac Care
Dr. George Chrysant, Chief Medical Officer at INTEGRIS Health Heart Hospital, also noted the significance of the ruling: "The reliability that comes with CMS's decision will significantly enhance the deployment of the CADScor System in emergency and ambulatory environments across the nation." He added that CMS's commitment to reassessing the reimbursement rates based on the technology's uptake solidifies its status as a vital diagnostic tool.
The expectation is that this ruling will set a precedent, not just for public funding, but potentially influencing private insurers to follow suit. As Mahmood indicated, this could trigger a domino effect wherein private payers across the U.S. might adjust their reimbursement policies favorably towards the CADScor System. This alignment aligns with Acarix's broader vision of expanding access to innovative cardiac diagnostics.
The CADScor System: A Changing Landscape in Diagnostics
The CADScor System, celebrated for its non-invasive and radiation-free approach, utilizes artificial intelligence to provide rapid assessments for coronary artery disease (CAD), achieving an impressive accuracy rate of 97% in under ten minutes. The system is already CE- and FDA-cleared, has garnered over 40 patents, and has been implemented in more than 40,000 patients presenting with chest pain. This assures high reliability and patient safety, crucial factors in the medical field.
Future Prospects for Acarix
With the CADScor System poised for growth and wider acceptance within the U.S. healthcare system, Acarix is on an upward trajectory. The potential market expansion is vast, given the critical need for efficient diagnostic services amid rising demand for cardiac health management. Through their focused innovation and commitment to patient-centered care, Acarix is set to enhance how coronary artery disease is diagnosed and treated.
For detailed inquiries, individuals can reach out to Ashley Wilson at +1405 413 5201, or via email at awilson@saxum.com.
Frequently Asked Questions
What is the CADScor System?
The CADScor System is a non-invasive diagnostic tool that helps rule out coronary artery disease with high accuracy using AI technology.
How does the new CMS ruling affect Acarix?
The ruling allows Acarix to receive guaranteed reimbursement for the CADScor System, leading to potential growth in various healthcare settings.
What are the benefits of the CADScor System?
It offers fast, accurate diagnosis without radiation, aiding in timely decision-making for patients experiencing chest pain.
Who should consider using the CADScor System?
This system is suitable for patients presenting with symptoms related to coronary artery disease, particularly in emergency and outpatient settings.
How can I get more information about Acarix?
For inquiries, you can contact Ashley Wilson at +1405 413 5201, or reach out via email at awilson@saxum.com.
